DOCSLIB.ORG

Drug Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Formulary Drug Formulary Manufacturer: Medication: Manufacturer: Medication: ABBVIE Androgel ASSERTIO THERAPEUTICS Cambria ABBVIE Creon ASSERTIO THERAPEUTICS Gralise ABBVIE Humira ASSERTIO THERAPEUTICS Nucynta ER ADAPT PHARMA Narcan ASSERTIO THERAPEUTICS Zipsor AKORN Azasite ASTELLAS Myrbetriq AKORN Cosopt ASTELLAS Vesicare ALFASIGMA USA Cerefolin ASTRAZENECA Bevespi ALFASIGMA USA Deplin ASTRAZENECA Byduron ALFASIGMA USA Metanx ASTRAZENECA Daliresp ALLERGAN Acuvail ASTRAZENECA Farxiga ALLERGAN Alphagam ASTRAZENECA Movantik ALLERGAN Androderm ASTRAZENECA Tudorza ALLERGAN Bystolic ASTRAZENECA LP Brilanta ALLERGAN Combigan ASTRAZENECA LP Pulmicort ALLERGAN Delzicol ASTRAZENECA LP Symbicort ALLERGAN Fetzima AVANIR PHARMACEUTICALS, LLC Nuedexta ALLERGAN Gelnique AVANIR PHARMACEUTICALS, LLC Onzetra ALLERGAN Lastacaft BAUSCH HEALTH Alrex ALLERGAN Linzess BAUSCH HEALTH Aplenzin ALLERGAN Lumigan BAUSCH HEALTH Ativan ALLERGAN Namenda XR BAUSCH HEALTH Besivance ALLERGAN Namzaric BAUSCH HEALTH Elidel ALLERGAN Pylera BAUSCH HEALTH Istalol ALLERGAN Rapaflo BAUSCH HEALTH Lotemax ALLERGAN Savella BAUSCH HEALTH Luzu ALLERGAN Viberzi BAUSCH HEALTH Prolenza ALLERGAN Viibyrd BAUSCH HEALTH Relistor ALMATICA Napelan BAUSCH HEALTH Trulance AMARIN PHARMA Vascepa BAUSCH HEALTH Wellbutrin XL AMGEN Corlanor BIODELIVERY SCIENCES Belbuca AMGEN Repatha BIODELIVERY SCIENCES Bunavil AMNEAL SPECIALTY Zomig BIOVENTUS Supartz ANTARES PHARMA Otrexup B-M SQUIBB U.S. (PRIMARY CARE) Coumadin ARBOR PHARMACEUTICALS Edarbi B-M SQUIBB U.S. (PRIMARY CARE) Eliquis ARBOR PHARMACEUTICALS Edarbyclor BOEHRINGER INGELHEIM Combent ARBOR PHARMACEUTICALS Eveko BOEHRINGER INGELHEIM Jardiance ARBOR PHARMACEUTICALS Horizant BOEHRINGER INGELHEIM Pradaxa PO Box 338, Methuen, MA 01844-0338 | 888-321-7945 | www.IWPharmacy.com Revised August 2019 Drug Formulary Manufacturer: Medication: Manufacturer: Medication: BOEHRINGER INGELHEIM Spiriva LILLY Cialis BOEHRINGER INGELHEIM Stiolto LILLY Forteo BOEHRINGER INGELHEIM Tradjenta LILLY Humalog BRAINTREE LAB Suprep LILLY Humulin COLLEGIUM PHARMACEUTICALS Nucynta LILLY Trulicity COLLEGIUM PHARMACEUTICALS Xtampza MERCK SHARP & DOHME Asmanex CROWN LABORATORIES Ala Scalp MERCK SHARP & DOHME Belsmora CUMBERLAND PHARMACEUTICALS Kristalose MERCK SHARP & DOHME Dulera DEPUY MITEK Monovisc MERCK SHARP & DOHME Janumet DEPUY MITEK Orthovisc MERCK SHARP & DOHME Januvia EGALET US Arymo MYLAN SPECIALTY L.P. Dymista EGALET US Oxaydo MYLAN SPECIALTY L.P. Epipen ENDO PHARMACEUTICALS Nascobal MYLAN SPECIALTY L.P. Muse FERRING Eufelexxa MYLAN SPECIALTY L.P. Performomist GALDERMA Mirvaso NEOS THERAPEUTICS BRANDS Adzenys GALDERMA Oracea NEOS THERAPEUTICS BRANDS Cotempla GILEAD SCIENCES Descovy NODEN PHARMA USA Tekturna GILEAD SCIENCES Genvoya NODEN PHARMA USA Tekturn HCT GILEAD SCIENCES Ranexa NOVARTIS Ciprodex GLAXO SMITH KLINE Advair NOVARTIS Diovan GLAXO SMITH KLINE Anoro NOVARTIS Entresto GLAXO SMITH KLINE Arunity NOVARTIS Ilevro GLAXO SMITH KLINE Flovent NOVARTIS Pazeo GLAXO SMITH KLINE Incruse NOVARTIS Tobradex GLAXO SMITH KLINE Serevent NOVARTIS Travatan GLAXO SMITH KLINE Trelegy NOVO NORDISK Levemir GLAXO SMITH KLINE Ventolin HFA NOVO NORDISK Novofine INDIVIOR INC Suboxone NOVO NORDISK Novolog IRONWOOD PHARMACEUTICALS Zurampic NOVO NORDISK Novotwist JANSSEN Duragesic NOVO NORDISK Saxenda JANSSEN Invokaka NOVO NORDISK Tresiba JANSSEN Xarelto NOVO NORDISK Victoza JANSSEN PRODUCTS Procrit OREXO US Zubsolv KOWA PHARMACEUTICALS AMERICA Livalo OTSUKA AMERICA Rexulti LIFESCAN INC One Touch Test Strips P & G HEALTH Prilosec OTC LIFESCAN INC One Touch Lancets PERNIX THERAPEUTICS Silenor LILLY Adcirca PERNIX THERAPEUTICS Treximet PO Box 338, Methuen, MA 01844-0338 | 888-321-7945 | www.IWPharmacy.com Revised August 2019 Drug Formulary Manufacturer: Medication: Manufacturer: Medication: PFIZER CONSUMER HEALTHCARE Nexium SANOFI PHARMACEUTICALS Praluent PFIZER U.S. Celebrex SANOFI PHARMACEUTICALS Toujeo PFIZER U.S. Dilantin SANOFI-AVENTIS U.S. Lantus PFIZER U.S. Embeda SHIRE US INC. Vyvanse PFIZER U.S. Flector SPECGX Restoril PFIZER U.S. Genotropin SUN PHARMACEUTICALS Bromsite PFIZER U.S. Lipitor SUNOVION PHARMACEUTICALS Latuda PFIZER U.S. Lyrica SUNOVION PHARMACEUTICALS Seebri PFIZER U.S. Norvasc SUPERNUS PHARMACEUTICALS Oxtellar PFIZER U.S. Premarin SUPERNUS PHARMACEUTICALS Trokendi PFIZER U.S. Toviaz TAKEDA PHARMACEUTICALS Amitizia PFIZER U.S. Xeljanz TAKEDA PHARMACEUTICALS Dexilant PROMIUS PHARMA Zembrace TAKEDA PHARMACEUTICALS Trintellix PURDUE PHARMA L.P. Butrans TEVA RESPIRATORY Proair PURDUE PHARMA L.P. Hysingla TEVA RESPIRATORY Qnasal PURDUE PHARMA L.P. Oxycontin TEVA RESPIRATORY Qvar PURDUE PHARMA L.P. Symproic UCB PHARMA Briviact ROCHE DIAGNOSTICS Softclix UCB PHARMA Neupro SANKYO Morphabond UCB PHARMA Vimpat SANKYO Welchol UPSHER-SMITH Qudexy PO Box 338, Methuen, MA 01844-0338 | 888-321-7945 | www.IWPharmacy.com Revised August 2019 .
Load more

Recommended publications
  • Pharmaceutical and Medical Device Tort Practice Trusted Advisors to the Health Sciences Industry
    Pharmaceutical and Medical Device Tort Practice Trusted Advisors to the Health Sciences Industry Today’s product liability cases reach far beyond one courtroom, requiring more than Product Liability a case-by-case approach. Because we take a strategic approach to litigation, King & “Law Firm of the Spalding’s product liability practice is recognized as one of the best in the nation. Year” in 2016 Recognizing that our clients need to protect their businesses, including the continued viability of their products in the marketplace, our lawyers work together with both Law360 our FDA & Life Sciences practice group and our Government Investigations team to provide a 360° defense. As one client noted, “Cases can spill over into other things _________________ like regulatory issues … King & Spalding can bring it all.” And we do. • The largest health law practice in the nation, according to the American Health Mass Tort / Class Lawyers Association, providing additional depth of experience on healthcare Action “Law Firm regulatory and litigation issues. of the Year” in 2015 • A stable of specialists in the relevant sciences, as well as former FDA and DEA regulatory officials who provide highly sophisticated support to our litigation defense. U.S. News & World • IP attorneys who successfully represent biotechnology and pharmaceutical Report clients in prosecuting, obtaining and defending patents. _________________ Trial Ready When Needed We add to our strategic approach a range of trial experience that is increasingly Life Sciences “Law unusual in firms of our size. We try cases every year throughout the nation. With four Firm of the Year” in Fellows in the American College of Trial Lawyers, an organization whose members 2017 are elected based on actual courtroom experience, we serve notice to opposing counsel that they should not count their cases as settled.
    [Show full text]
  • Abbvie Allergan Acquisition
    Creating a New Diversified Biopharmaceutical Company The Combination of AbbVie and Allergan Investor Presentation June 25, 2019 NO OFFER OR SOLICITATION This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme Document. IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document.
    [Show full text]
  • Purdue Pharma to Pay $270 Million to Settle Historic Oklahoma Opioid Lawsuit
    Purdue Pharma to pay $270 million to settle historic Oklahoma opioid lawsuit (CNN) — Purdue Pharma has agreed to pay $270 million to settle a historic lawsuit brought by the Oklahoma attorney general, who accused the OxyContin maker of aggressively marketing the opioid painkiller and fueling a drug epidemic that left thousands dead in the state. The settlement comes after Purdue fought the attorney general in court, seeking to delay the start of the trial, which is scheduled for May 28. "It is a new day in Oklahoma, and for the nation, in our battle against addiction and the opioid epidemic," Attorney General Mike Hunter said Tuesday in Tulsa. Hunter said that $102.5 million of the settlement would be used to help establish a national addiction treatment and research center at Oklahoma State University, with additional payments of $15 million each year for the next five years beginning in 2020. The company will also provide $20 million of addiction treatment and opioid rescue medications to the center over the same five-year time frame. A remaining $12.5 million from the settlement will be used directly to help cities and counties with the opioid crisis. The Sackler family, who founded and own Purdue Pharma, will also contribute $75 million over the next five years to the treatment and research center. "Purdue is very pleased to have reached an agreement with Oklahoma that will help those who are battling addiction now and in the future," Dr. Craig Landau, president and CEO of Purdue Pharma, said in a statement. The lawsuit was brought by Hunter against some of the nation's leading makers of opioid pain medications, alleging that deceptive marketing over the past decade fueled the epidemic in the state.
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • Product Hopping 2.0: Getting the FDA to Yank Your Original License Beats Stacking Patents Lars Noah
    Marquette Intellectual Property Law Review Volume 19 | Issue 2 Article 2 Product Hopping 2.0: Getting the FDA To Yank Your Original License Beats Stacking Patents Lars Noah Follow this and additional works at: http://scholarship.law.marquette.edu/iplr Part of the Intellectual Property Commons Repository Citation Lars Noah, Product Hopping 2.0: Getting the FDA To Yank Your Original License Beats Stacking Patents, 19 Marq. Intellectual Property L. Rev. 161 (2015). Available at: http://scholarship.law.marquette.edu/iplr/vol19/iss2/2 This Article is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. It has been accepted for inclusion in Marquette Intellectual Property Law Review by an authorized administrator of Marquette Law Scholarly Commons. For more information, please contact [email protected]. NOAH FINAL (DO NOT DELETE) 5/9/2015 4:17 PM ARTICLES PRODUCT HOPPING 2.0: GETTING THE FDA TO YANK YOUR ORIGINAL LICENSE BEATS STACKING PATENTS LARS NOAH* INTRODUCTION .............................................................................................. 165 I.A PRIMER ON PRODUCT HOPPING IN THE PHARMACEUTICAL INDUSTRY ... 165 II. NEW & IMPROVED PRODUCT HOPPING: THE OXYCONTIN MANEUVER ... 172 CONCLUSION .................................................................................................. 179 * Professor of Law, University of Florida. NOAH FINAL (DO NOT DELETE) 5/9/2015 4:17 PM 162 MARQ. INTELL. PROP. L. REV. [Vol. 19:2 NOAH FINAL (DO NOT DELETE) 5/9/2015 4:17 PM 2015] PRODUCT HOPPING 2.0 163 Lars Noah is a Professor of Law at the Univeersity of Florida, where he has taught courses in Administrative Law, Biommedical Innoovation, Medical Technology, Public Health Law, and Torts, among other subjects.
    [Show full text]
  • The Covid–19 Pandemic and Haemoglobin Disorders
    THE COVID–19 PANDEMIC AND HAEMOGLOBIN DISORDERS VACCINATIONS & THERAPEUTIC DRUGS An Informational Guide from the Thalassaemia International Federation (TIF) Prepared by: Dr Androulla Eleftheriou, Executive Director, TIF Last Updated: 12 May 2020 VACCINATIONS & THERAPEUTIC DRUGS Introduction It is important to note that there are currently no FDA1 or EMA2-approved or even recommended agents for the treatment of the novel coronavirus (COVID-19), for which the World Health Organization (WHO) declared as pandemic on Wednesday 11th of March 2020. Any agent being used at this time is being administered in an experimental setting under controlled conditions. Thalassaemia International Federation (TIF) has made an effort to compile a list of studies/clinical trials for treatment and vaccines, which is by no means exhaustive as this situation is extremely labile and research in this area is dramatically intensified. New information is anticipated to be added to this guide which is prepared exclusively for TIF’s global thalassemia community. The viral genome was mapped very soon as rom early January 2020 and shared globally. In February 2020, the WHO published an overview of the potential therapeutic candidates for the treatment of COVID-19. The document outlines 76 regimens that have been proposed (as of February 17, 2020) for the treatment of patients infected with the virus. Thirty-eight of these candidates are in the preclinical state with minimal information available on their proposed mechanism, uses, doses routes, or planned trials. Sixteen of the remaining regimens contain an interferon-based product. The rest include a variety of antimicrobials, corticosteroids, convalescent plasma, and biologics. The Director-General of the WHO, Mr Tedros Adhanom, stated on the 10th of April 2020, that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and 20 Institutions and companies ‘are racing to develop a vaccine’.
    [Show full text]
  • PURDUE PHARMA, L.P., a Delaware Limited Partnership, PURDUE PHARMA INC., a New York Corporation, and RICHARD SACKLER, M.D
    IN THE CIRCUIT COURT OF BOONE COUNTY, WEST VIRGINIA STATE OF WEST VIRGINIA ex rel. PATRICK MORRISEY, Attorney General, Plaintiff, v. CIVIL ACTION NO. JUDGE PURDUE PHARMA, L.P., a Delaware limited partnership, PURDUE PHARMA INC., a New York corporation, and RICHARD SACKLER, M.D. Defendants. COMPLAINT This action is brought in the name of the State of West Virginia in its sovereign capacity by Patrick Morrisey, Attorney General, pursuant to W. Va. Code § 46A-7-108 of the West Virginia Consumer Credit and Protection Act, W. Va. Code § 46A- 1-101 et seq. ("WVCCPA"), against Purdue Pharma L.P., Purdue Pharma Inc., and Richard Sackler, M.D., to protect consumers and the integrity of the commercial marketplace in West Virginia. This action is brought against Richard Sackler individually and as a director on the Board of Purdue Pharma, Inc. The State also brings suit pursuant to the Attorney General's common law police power to abate and remedy the statewide public nuisance created by the Defendants' interference with the commercial marketplace and endangerment of the public health. BACKGROUND 1. In June 2001, the State of West Virginia, the Bureau of Employment Programs, West Virginia Department of Health and Human Services and the West Virginia Public Employees Insurance Agency sued Purdue Pharma L.P., Purdue Pharma Inc., and Purdue Frederick Company in the Circuit Court of McDowell County, West Virginia, Civil Action No. 01-C-137-S, for violations of the WVCCPA, in connection with the sale and marketing of OxyContin®. The parties entered into a settlement agreement that was approved by Final Order dated December 22, 2004 ("2004 Settlement").
    [Show full text]
  • COVID-19 Treatment and Vaccine Tracker This Document Contains an Aggregation of Publicly Available Information from Validated Sources
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES PhRMA Begin Phase 1 trials in late Polyclonal hyperimmune Alliance among Takeda, CSL Behring, Wall Street Journal spring. To patients between 1 globulin (H-IG), formerly N/A Biotest AG, Bio Products Laboratory, Pre-clinical Pink Sheet December 2020 and December known at TAK-888 LFB, and Octapharma Press release from the 2021 alliance Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Korea Herald Antibodies from recovered 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 UPI COVID-19 patients Celltrion press release Super-antibody or antibody 4 cocktail to target potential N/A Celltrion Pre-clinical Celltrion press release mutations of SARS-CoV-2 Antibodies from recovered BioSpace 5 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 6 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources.
    [Show full text]
  • Case 1:17-Cv-00450-UNA Document 1 Filed 04/20/17 Page 1 of 18 Pageid #: 1
    Case 1:17-cv-00450-UNA Document 1 Filed 04/20/17 Page 1 of 18 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PURDUE PHARMA L.P., PURDUE ) PHARMACEUTICALS L.P., THE P.F. ) LABORATORIES, INC., and RHODES ) TECHNOLOGIES, ) ) Plaintiffs, ) C.A. No. __________________ v. ) ) ABHAI, LLC and KVK-TECH, INC., ) ) Defendants. ) COMPLAINT Plaintiffs Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc. (collectively, “Purdue”), and Rhodes Technologies (“Rhodes”) (collectively, “Plaintiffs”), for their Complaint against Defendants Abhai, LLC (“Abhai”) and KVK-TECH, Inc. (“KVK”) (collectively, “Defendants”), aver as follows: NATURE OF THE ACTION 1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, for infringement of United States Patent Nos. 9,492,389 (“the ’389 patent”); 9,492,391 (“the ’391 patent”); 9,492,392 (“the ’392 patent”); 9,492,393 (“the ’393 patent”) and 9,522,919 (“the ’919 patent”) (collectively, “the patents-in- suit”). This action relates to Abbreviated New Drug Application (“ANDA”) No. 207493 (“Defendants’ ANDA”) submitted upon information and belief in the name of Defendants to the United States Food and Drug Administration (“FDA”). 2. Plaintiffs seek judgment that Defendants have infringed the ’389, ’391, ’392, ’393, and ’919 patents, which are listed in the FDA Approved Drug Products With Case 1:17-cv-00450-UNA Document 1 Filed 04/20/17 Page 2 of 18 PageID #: 2 Therapeutic Equivalence Evaluations (“Orange Book”) as covering Purdue’s OxyContin® (oxycodone hydrochloride) (“OxyContin®”), an extended-release pain medication.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]